PRRT2 and cancer: Together with the reported nontranscriptional EMT effects mediated by this PKC, such as stabilization of E-cadherin at adherent junctions (253), these findings have significant therapeutic implications, since inhibition of PKCα-mediated signaling may reverse the mesenchymal phenotype and ultimately sensitize cancer cells to therapy (139, 246, 252, 254, 255).